Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, Massachusetts.
Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts.
Biol Blood Marrow Transplant. 2019 Jan;25(1):e17-e22. doi: 10.1016/j.bbmt.2018.10.022. Epub 2018 Nov 5.
Disruption of the intestinal microbiome early after allogeneic hematopoietic cell transplantation (allo-HCT) has been linked to adverse outcomes in transplant recipients. To date, whether microbiome-directed interventions will be able to impact important clinical endpoints remains unknown. Fecal microbiota transplantation (FMT) is a compelling intervention to restore healthy diversity to the intestinal microenvironment after allo-HCT, but currently has no established role in transplant recipients. In this review, we examine the use of FMT as treatment for Clostridium difficile infection and acute graft-versus-host disease, and also as a restorative intervention early after allo-HCT. Ongoing and planned studies will help determine the ultimate role of FMT in allo-HCT recipients.
异基因造血细胞移植（allo-HCT）后早期肠道微生物组的破坏与移植受者的不良结局有关。迄今为止，微生物组导向的干预措施是否能够影响重要的临床终点仍不清楚。粪便微生物群移植（FMT）是一种很有前途的干预措施，可以在 allo-HCT 后恢复肠道微环境的健康多样性，但目前在移植受者中尚无确定的作用。在这篇综述中，我们研究了 FMT 作为治疗艰难梭菌感染和急性移植物抗宿主病的治疗方法，以及作为 allo-HCT 后早期的恢复性干预措施。正在进行和计划中的研究将有助于确定 FMT 在 allo-HCT 受者中的最终作用。
